Niagen Bioscience, Inc. (NAGE) Q1 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Niagen Bioscience, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:01.853 -- 00:00:06.678 Ladies and gentlemen, thank you for standing by, and welcome to Niagen Biosciences, Inc.' 00:00:06.678 -- 00:00:10.923 's first quarter of 2025 earnings conference call. 00:00:10.923 -- 00:00:13.426 My name is Kayla, and I will be the conference operator today. 00:00:13.426 -- 00:00:18.492 At this time, all participants are in a listen-only mode, and as a reminder, this 00:00:18.492 -- 00:00:23.737 conference call is being recorded. This afternoon, Niagen Biosciences issued 00:00:23.737 -- 00:00:29.478 a news release announcing the company's financial results for the first quarter of 2025. 00:00:29.478 -- 00:00:33.944 If you have not reviewed this information, both are available within the Investor Relations 00:00:33.944 -- 00:00:39.548 section of Niagen Bioscience's website at www.niagensbioscience.com. 00:00:41.533 -- 00:00:46.580 I would now like to turn the conference call over to Wesley Yu, Vice President of Finance. 00:00:46.580 -- 00:00:49.701 Please go ahead, Mr. Yu. 00:00:50.344 -- 00:00:55.551 Thank you. Good afternoon, and welcome to Niagen Bioscience's first quarter of 2025 00:00:55.551 -- 00:01:00.726 conference call. With us today are Nijen Biosciences Chief Executive 00:01:00.726 -- 00:01:06.231 Officer Rob Fried, Chief Financial Officer Ozan Tamir, and Senior 00:01:06.231 -- 00:01:09.574 Vice President of Scientific and Regulatory Affairs, Dr. 00:01:09.574 -- 00:01:14.877 Andrew Hsiao. Dr. Hsiao will join the call for Q&A. 00:01:15.580 -- 00:01:19.143 Today's conference call may include forward-looking statements, including statements 00:01:19.143 -- 00:01:24.589 related to the company's research and development and clinical trial plans 00:01:24.589 -- 00:01:27.798 and the timing and results of such trials. 00:01:27...